-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on Mereo BioPharma Group, Raises Price Target to $8

Benzinga·08/25/2025 14:14:55
Listen to the news
JP Morgan analyst Priyanka Grover maintains Mereo BioPharma Group (NASDAQ:MREO) with a Overweight and raises the price target from $7 to $8.